Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fostamatinib Disodium

FDA-approved product (tablet, oral), marketed as Fostamatinib Disodium, Tavalisse.

Registered studies
27
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Fostamatinib Disodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Autoimmune thrombocytopenic purpura
  • Hemorrhage
  • Thrombocytopenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other systemic hemostatics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

27registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fostamatinib Disodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fostamatinib Disodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.

    NCT01197534 · start 2010-09

    Registered record
    Registry ID
    NCT01197534
    Conditions
    Rheumatoid Arthritis
    Interventions
    fostamatinib; fostamatinib; placebo, fostamatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-09
    Completion
    2013-03
    Enrolment
    913

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    Interventionfostamatinib; fostamatinib; placebo, fostamatinib
    PhasePhase 3
    Registry statusCompleted

  • Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

    NCT01197755 · start 2010-09

    Registered record
    Registry ID
    NCT01197755
    Conditions
    Rheumatoid Arthritis
    Interventions
    fostamatinib; fostamatinib; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-09
    Completion
    2013-02
    Enrolment
    323

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    Interventionfostamatinib; fostamatinib; placebo
    PhasePhase 3
    Registry statusCompleted

  • Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers

    NCT01197781 · start 2010-09

    Registered record
    Registry ID
    NCT01197781
    Conditions
    Drug Drug Interactions; Healthy Volunteers
    Interventions
    FOSTAMATIN; Verapamil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-09
    Completion
    2010-10
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Drug Interactions; Healthy Volunteers
    InterventionFOSTAMATIN; Verapamil
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects

    NCT01167868 · start 2010-07

    Registered record
    Registry ID
    NCT01167868
    Conditions
    Healthy
    Interventions
    FosD; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-07
    Completion
    2011-05
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionFosD; Placebo
    PhasePhase 1
    Registry statusCompleted

  • A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...

    NCT00923481 · start 2009-04

    Registered record
    Registry ID
    NCT00923481
    Conditions
    Head and Neck Neoplasms; Pheochromocytoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell
    Interventions
    Fostamatinib disodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-04
    Completion
    2012-01
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Neoplasms; Pheochromocytoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung +1 more
    InterventionFostamatinib disodium
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma

    NCT00798096 · start 2009-03

    Registered record
    Registry ID
    NCT00798096
    Conditions
    T Cell Lymphoma
    Interventions
    Fostamatinib Disodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-04
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionT Cell Lymphoma
    InterventionFostamatinib Disodium
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus

    NCT00752999 · start 2008-11

    Registered record
    Registry ID
    NCT00752999
    Conditions
    Systemic Lupus Erythematosus
    Interventions
    Fostamatinib Disodium (R935788); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2008-11
    Completion
    2010-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Lupus Erythematosus
    InterventionFostamatinib Disodium (R935788); Placebo
    PhasePhase 2
    Registry statusWithdrawn

  • Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies

    NCT00805467 · start 2008-08

    Registered record
    Registry ID
    NCT00805467
    Conditions
    Rheumatoid Arthritis
    Interventions
    Fostamatinib Disodium (R935788)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2008-08
    Completion
    2013-08
    Enrolment
    624

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionFostamatinib Disodium (R935788)
    PhasePhase 2
    Registry statusTerminated

  • Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)

    NCT00665626 · start 2008-05

    Registered record
    Registry ID
    NCT00665626
    Conditions
    Rheumatoid Arthritis
    Interventions
    Fostamatinib disodium (R935788); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-05
    Completion
    2009-06
    Enrolment
    219

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionFostamatinib disodium (R935788); Placebo
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

    NCT00665925 · start 2008-05

    Registered record
    Registry ID
    NCT00665925
    Conditions
    Rheumatoid Arthritis
    Interventions
    Fostamatinib disodium (R935788); Fostamatinib disodium (R935788); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-05
    Completion
    2009-06
    Enrolment
    457

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionFostamatinib disodium (R935788); Fostamatinib disodium (R935788); Placebo
    PhasePhase 2
    Registry statusCompleted

  • Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)

    NCT00706342 · start 2007-01

    Registered record
    Registry ID
    NCT00706342
    Conditions
    Purpura, Thrombocytopenic, Idiopathic
    Interventions
    Fostamatinib Disodium / R935788
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-01
    Completion
    2010-04
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPurpura, Thrombocytopenic, Idiopathic
    InterventionFostamatinib Disodium / R935788
    PhasePhase 2
    Registry statusCompleted

  • Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

    NCT03363334

    Registered record
    Registry ID
    NCT03363334
    Conditions
    Immune Thrombocytopenic Purpura
    Interventions
    Fostamatinib disodium 100 mg; Fostamatinib disodium 150 mg
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmune Thrombocytopenic Purpura
    InterventionFostamatinib disodium 100 mg; Fostamatinib disodium 150 mg
    PhaseNot recorded
    Registry statusNo longer available